We are live on ! Find out more
PRLD icon

Prelude Therapeutics
PRLD

60 hedge funds and large institutions have $1.41B invested in Prelude Therapeutics in 2021 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 30 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 8

113% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 8

18% more funds holding

Funds holding: 51 → 60 (+9)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

9.44% less ownership

Funds ownership: 79.29% → 69.85% (-9.4%)

43% less capital invested

Capital invested by funds: $2.47B → $1.41B (-$1.06B)

Holders
60
Holders Change
+9
Holders Change %
+17.65%
% of All Funds
1.05%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
17
Increased
30
Reduced
8
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$135M
2
State Street
State Street
Massachusetts
+$48.5M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$13.8M
4
Federated Hermes
Federated Hermes
Pennsylvania
+$12.3M
5
UBS AM
UBS AM
Illinois
+$8.42M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$369M
2
HA
HHLR Advisors
Cayman Islands
-$8.19M
3
SCM
Suvretta Capital Management
New York
-$7.95M
4
CCM
CAAS Capital Management
New York
-$3.58M
5
Squarepoint
Squarepoint
New York
-$1.48M
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$439M +$344K +5,188 +0.1%
O
2
OrbiMed
New York
$435M -$369M -5,555,186 -36%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$271M +$135M +2,042,144 +49%
State Street
4
State Street
Massachusetts
$37.8M +$48.5M +731,043 +514%
Vanguard Group
5
Vanguard Group
Pennsylvania
$37.6M +$13.8M +207,575 +31%
BlackRock
6
BlackRock
New York
$29.5M +$2.96M +44,592 +7%
UBS AM
7
UBS AM
Illinois
$27.9M +$8.42M +126,950 +25%
HA
8
HHLR Advisors
Cayman Islands
$27.1M -$8.19M -123,498 -16%
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
$18.3M +$2.34M +35,311 +9%
RSCM
10
Rock Springs Capital Management
Maryland
$16.4M +$1.18M +17,832 +5%
Federated Hermes
11
Federated Hermes
Pennsylvania
$14.6M +$12.3M +186,100 +124%
Massachusetts Financial Services
12
Massachusetts Financial Services
Massachusetts
$12.2M -$201K -3,023 -1%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$8.63M +$502K +7,563 +4%
Northern Trust
14
Northern Trust
Illinois
$5M +$31.6K +476 +0.4%
Charles Schwab
15
Charles Schwab
California
$3.24M +$405K +6,100 +9%
Citigroup
16
Citigroup
New York
$2.63M +$3.91M +58,866 +3,401%
Rafferty Asset Management
17
Rafferty Asset Management
New York
$2.1M +$3.21M +48,450 New
Goldman Sachs
18
Goldman Sachs
New York
$1.89M +$2.89M +43,509 New
N
19
Nuveen
North Carolina
$1.62M +$174K +2,624 +8%
Deutsche Bank
20
Deutsche Bank
Germany
$1.58M +$1.98M +29,836 +442%
Bank of New York Mellon
21
Bank of New York Mellon
New York
$1.34M +$4.18K +63 +0.2%
Marshall Wace
22
Marshall Wace
United Kingdom
$1.27M +$1.94M +29,315 New
TD Asset Management
23
TD Asset Management
Ontario, Canada
$1.23M +$393K +5,931 +26%
Norges Bank
24
Norges Bank
Norway
$1.08M +$332K +5,000 +25%
Morgan Stanley
25
Morgan Stanley
New York
$1.04M -$203K -3,054 -11%
1
2 3

PRLD Hedge Fund Activity: Q1 2021 in Review

60 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q1 2021, worth a combined $1.41B — down 43% from $2.47B a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new PRLD positions and 8 closed out — a net gain of 9 holders — while 30 added to existing stakes and 8 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $135M. The largest seller was OrbiMed, cutting an estimated $369M.

  • 60 institutional investors held Prelude Therapeutics (PRLD) as of Q1 2021, up from 51 in Q4 2020.
  • Funds reported $1.41B of Prelude Therapeutics stock for Q1 2021, down 43% quarter-over-quarter.
  • 17 funds opened new Prelude Therapeutics positions in Q1 2021 and 8 closed out, a net change of +9 holders.
  • The largest Prelude Therapeutics buyer in Q1 2021 was Fidelity Investments, an estimated $135M added.
  • The largest Prelude Therapeutics seller in Q1 2021 was OrbiMed, an estimated $369M sold.

Based on aggregated 13F filings for Q1 2021.